Zimmer Partners, LP Taysha Gene Therapies, Inc. Transaction History
Zimmer Partners, LP
- $4.52 Billion
- Q1 2025
Shares
2 transactions
Others Institutions Holding TSHA
# of Institutions
125Shares Held
153MCall Options Held
70KPut Options Held
4.7K-
Avoro Capital Advisors LLC New York, NY20MShares$54 Million0.45% of portfolio
-
Rtw Investments, LP New York, NY18.8MShares$50.7 Million0.43% of portfolio
-
Morgan Stanley New York, NY16.8MShares$45.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$31.7 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$29.4 Million0.31% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $131M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...